|
|
戈谢病骨损害发病机制及诊治的研究进展
|
Abstract:
戈谢病是一种溶酶体贮积症，属于常染色体隐性遗传病。该病起病原因是葡萄糖脑苷脂酶基因发生突变，导致溶酶体内葡萄糖脑苷脂酶缺乏，葡萄糖脑苷脂无法被正常水解，在肝脏、脾脏、骨骼、脑组织的巨噬细胞溶酶体中贮积，形成戈谢细胞，戈谢细胞浸润组织器官进而引发肝脏肿大、脾脏肿大、骨骼损害、癫痫等。戈谢病患儿骨损害发生率高，严重影响患儿的生长发育及生存质量，因此，本文将对戈谢病骨损害的机制、临床表现、评估以及防治的研究进展作一综述，以期提高对戈谢病骨损害的认识。
Gaucher disease is a lysosomal storage disease, which belongs to autosomal recessive disease. The onset of the disease is due to the mutation of glucocerebrosidase gene, resulting in the lack of glucocerebrosidase in lysosomes. Glucocerebroside can not be hydrolyzed normally and is stored in macrophage lysosomes of liver, spleen, bone and brain to form Gaucher cells. Gaucher cells infiltrate tissues and organs, resulting in hepatomegalyt, splenomegaly, bone damage, epilepsy, etc. The incidence of bone damage in children with gaucher disease is high, which seriously affects the growth, development and quality of life of children. Therefore, this paper will review the research progress of the mechanism, clinical manifestation, evaluation, prevention and treatment of bone damage in gaucher disease, in order to improve the understanding of bone damage in gaucher disease.
| [1] | 商春阳, 陈春雷, 贾敦茂, 乔海泉. 戈谢病治疗方式研究进展[J]. 中华普通外科杂志, 2018, 33(5): 442-444. |
| [2] | 吴小英, 甘川, 许红梅, 张祯祯. 不同类型戈谢病患儿感染风险差异分析[J]. 中国循证儿科杂志, 2021, 16(2): 152-155. |
| [3] | Biegstraaten, M., Cox, T.M., Belmatoug, N., Berger, M.G., Collin-Histed, T., Vom Dahl, S., et al. (2016) Management Goals for Type 1 Gaucher Disease: An Expert Consensus Document from the European Working Group on Gaucher Disease. Blood Cells, Molecules, and Diseases, 68, 203-208. https://doi.org/10.1016/j.bcmd.2016.10.008 |
| [4] | Belmatoug, N., Di Rocco, M., Fraga, C., Giraldo, P., Hughes, D., Lukina, E., et al. (2017) Management and Monitoring Recommendations for the Use of Eliglustat in Adults with Type 1 Gaucher Disease in Europe. European Journal of Internal Medicine, 37, 25-32. https://doi.org/10.1016/j.ejim.2016.07.011 |
| [5] | Clarke, L.A. and Hollak, C.E.M. (2015) The Clinical Spectrum and Pathophysiology of Skeletal Complications in Lysosomal Storage Disorders. Best Practice & Research Clinical Endocrinology & Metabolism, 29, 219-235.
https://doi.org/10.1016/j.beem.2014.08.010 |
| [6] | Durnas, B., Watek, M., Wollny, T., Niemirowicz, K., Marzec, M., Bucki, R., et al. (2016) Utility of Blood Procalcitonin Concentration in the Management of Cancer Patients with Infections. OncoTargets and Therapy, 9, 469-475.
https://doi.org/10.2147/OTT.S95600 |
| [7] | Mistry, P.K., Taddei, T., vom Dahl, S. and Rosenbloom, B.E. (2013) Gaucher Disease and Malignancy: A Model for Cancer Pathogenesis in an Inborn Error of Metabolism. Critical Re-views？ in Oncogenesis, 18, 235-246.
https://doi.org/10.1615/CritRevOncog.2013006145 |
| [8] | Pandey, M.K. and Grabowski, G.A. (2013) Immuno-logical Cells and Functions in Gaucherdisease. Critical Reviews？ in Oncogenesis, 18, 197-220. https://doi.org/10.1615/CritRevOncog.2013004503 |
| [9] | Arends, M., van Dussen, L., Biegstraaten, M. and Hollak, C.E.M. (2013) Malignancies and Monoclonal Gammopathy in Gaucher Disease; A Systematic Review of the Literature. British Journal of Haematology, 161, 832-842.
https://doi.org/10.1111/bjh.12335 |
| [10] | Nair, S., Branagan, A.R., Liu, J., Boddupalli, C.S., Mistry, P.K. and Dhodapkar, M.V. (2016) Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. New England Journal of Medicine, 374, 555-561.
https://doi.org/10.1056/NEJMoa1508808 |
| [11] | Kyle, R.A., Larson, D.R., Therneau, T.M., Dispenzieri, A., Kumar, S., et al. (2018) Long-Term Follow-Up of Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine, 378, 241-249.
https://doi.org/10.1056/NEJMoa1709974 |
| [12] | Masi, L. and Brandi, M.L. (2015) Gaucher Disease: The Role of the Specialist on Metabolic Bone Diseases. Clinical Cases in Mineral and Bone Metabolism, 12, 165-169. https://doi.org/10.11138/ccmbm/2015.12.2.165 |
| [13] | Jeon, O.H., Panicker, L.M., Lu, Q., Chae, J.J., Feldman, R.A. and Elisseeff, J.H. (2016) Human iPSC-Derived Osteoblasts and Osteoclasts Together Promote Bone Regeneration in 3D Biomaterials. Scientific Reports, 6, Article No. 26761.
https://doi.org/10.1038/srep26761 |
| [14] | Srivastava, R.K., Dar, H.Y. and Mishra, P.K. (2018) Immunoporosis: Immunology of Osteoporosis-Role of T Cells. Frontiers in Immunology, 9, Article No. 657. https://doi.org/10.3389/fimmu.2018.00657 |
| [15] | Ponzetti, M. and Rucci, N. (2019) Updates on Osteoimmunology: What’s New on the Cross-Talk between Bone and Immune System. Frontiers in Endocrinology, 10, Article No. 236. https://doi.org/10.3389/fendo.2019.00236 |
| [16] | Yang, A.C., Bier, L., Overbey, J.R., Cohen-Pfeffer, J., Desai, K., Desnick, R.J., et al. (2017) Early Manifestations of Type 1 Gaucher Disease in Presymptomatic Children Diagnosed after Parental Carrier Screening. Genetics in Medicine, 19, 652-658. https://doi.org/10.1038/gim.2016.159 |
| [17] | Khan, A., Hangartner, T., Weinreb, N.J., Taylor, J.S. and Mistry, P.K. (2012) Risk Factors for Fractures and Avascular Osteonecrosis in Type 1 Gaucher Disease: A Study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Journal of Bone and Mineral Research, 27, 1839-1848. https://doi.org/10.1002/jbmr.1680 |
| [18] | Kallish, S. and Kaplan, P. (2013) A Disease Severity Scoring System for Children with Type 1 Gaucher Disease. European Journal of Pediatrics, 172, 39-43. https://doi.org/10.1007/s00431-012-1830-5 |
| [19] | Yoshida, S., Kido, J., Matsumoto, S., Momosaki, K., Mitsubuchi, H., Shimazu, T., et al. (2016) Prenatal Diagnosis of Gaucher Disease Using Next-Generation Sequencing. Pediatrics International, 58, 946-949.
https://doi.org/10.1111/ped.13069 |
| [20] | Fuller, M., Szer, J., Stark, S. and Fletcher, J.M. (2015) Rapid, Sin-gle-Phase Extraction of Glucosylsphingosine from Plasma: A Universal Screening and Monitoring Tool. Clinica Chimica Acta, 450, 6-10.
https://doi.org/10.1016/j.cca.2015.07.026 |
| [21] | Mirzaian, M., Wisse, P., Ferraz, M.J., Gold, H., Donker-Koopman, W.E., Verhoek, M., et al. (2015) Mass Spectrometric Quantification of Glucosylsphingosine in Plasma and Urine of Type 1 Gaucher Patients Using an Isotope Standard. Blood Cells, Molecules, and Diseases, 54, 307-314. https://doi.org/10.1016/j.bcmd.2015.01.006 |
| [22] | Murugesan, V., Chuang, W.L., Liu, J., Lischuk, A., Kacena, K., Lin, H., et al. (2016) Glucosylsphingosine Is a Key Biomarker of Gaucher Disease. American Journal of Hematology, 91, 1082-1089. https://doi.org/10.1002/ajh.24491 |
